Park National Corp OH Sells 1,995 Shares of Bristol-Myers Squibb (NYSE:BMY)


Share on StockTwits

Park National Corp OH cut its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 5.7% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 33,203 shares of the biopharmaceutical company’s stock after selling 1,995 shares during the period. Park National Corp OH’s holdings in Bristol-Myers Squibb were worth $2,096,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Retirement Group LLC bought a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $27,000. Orion Capital Management LLC bought a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $28,000. Perennial Advisors LLC bought a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $29,000. Founders Capital Management bought a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $31,000. Finally, Alpha DNA Investment Management LLC acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at approximately $33,000. Hedge funds and other institutional investors own 72.41% of the company’s stock.

NYSE BMY opened at $62.22 on Thursday. The company has a fifty day simple moving average of $61.76 and a two-hundred day simple moving average of $65.68. The stock has a market cap of $139.00 billion, a P/E ratio of -564.13, a P/E/G ratio of 1.00 and a beta of 0.67. Bristol-Myers Squibb has a 12-month low of $54.07 and a 12-month high of $67.16. The company has a current ratio of 1.67, a quick ratio of 1.58 and a debt-to-equity ratio of 0.82.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Wednesday, February 3rd. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.42 by $0.04. Bristol-Myers Squibb had a negative net margin of 0.11% and a positive return on equity of 27.48%. The firm had revenue of $11.07 billion during the quarter, compared to analysts’ expectations of $10.74 billion. During the same quarter last year, the company posted $1.22 earnings per share. The firm’s revenue was up 39.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Bristol-Myers Squibb will post 6.35 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, May 3rd. Investors of record on Thursday, April 1st will be issued a dividend of $0.49 per share. The ex-dividend date of this dividend is Wednesday, March 31st. This represents a $1.96 annualized dividend and a dividend yield of 3.15%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 41.79%.

In related news, CEO Giovanni Caforio sold 25,000 shares of the firm’s stock in a transaction on Monday, March 22nd. The shares were sold at an average price of $62.20, for a total transaction of $1,555,000.00. Following the completion of the transaction, the chief executive officer now owns 528,980 shares of the company’s stock, valued at $32,902,556. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.14% of the company’s stock.

Several equities research analysts have weighed in on BMY shares. TheStreet downgraded shares of Bristol-Myers Squibb from a “b” rating to a “c” rating in a research note on Monday, March 8th. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $66.00 target price for the company in a research note on Tuesday. Finally, The Goldman Sachs Group upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “conviction-buy” rating in a research note on Tuesday, December 15th. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. Bristol-Myers Squibb currently has an average rating of “Buy” and an average price target of $74.07.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.

Further Reading: How big is the FinTech market?

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.